Skip to main content

Table 2 Clinical characteristics

From: Cortico-cerebellar functional connectivity and sequencing of movements in schizophrenia

Group Dg. SCH/SAF (%) Duration Episodes Dose AP MARTA/SDA(%) BAS AIMS SAS AntiPark (%) NSS-T SI MC
SCH 21/3 (87.5/12.5) 9.2 (7.6) 4.2(2.0) 364.5 (203.1) 13/11 (54.2/45.8) 0.7 (1.9) 0 1.2 (1.3) 3 (12.5) 4.0 (2.4) 0.9 (1.4) 0.2 (0.5)
SQ+ 5/2 (71.4/28.6) 13.8 (7.2) 5.7(1.3)* 360.6 (195.8) 4/3(57.1/42.9) 0.6 (1.1) 0 1.7 (1.5) 1 (14.3) 5.9* (2.2) 0.3 (0.8) 0.4 (0.8)
SQ- 16/1 (94.1/5.9) 7.8 (7.4) 3.6(1.9) 366.1 (212.0) 9/8 (52.9/47.1) 0.7 (2.2) 0 1.0 (1.1) 2 (11.8) 3.2 (2.1) 1.1 (1.5) 0.06 (0.2)
  1. SCH- schizophrenia patients, SQ + schizophrenia patients with marked movement sequencing abnormalities (SQ score > 2), SQ- schizophrenia patients without movement sequencing abnormalities; SCH- schizophrenia, SAF- schizoaffective disorder; AP- antipsychotic medication, MARTA- multi-acting receptor-targeted antipsychotics, SDA- serotonin-dopamine antagonists; BAS- Barnes Akathisia Scale; AIMS- Abnormal Involuntary Movements Scale, SAS- Simpson-Angus Scale; AntiPark- antiparkinsonian medication; NSS-T- neurological soft signs total score, SI- sensory integration, MC- motor coordination, SQ- movements sequencing. * p < 0.05, ** p < 0.001 - significance level for group comparisons (SQ + vs. SQ-)